randomised clinical trials assessed the treatment-independent trends for overall colon cleansing quality versus overall colon lesion detection.

Methods Three multi-centre phase 3 clinical trials compared the cleansing efficacy and safety of the 1L PEG NER1006 (PLENVU®) versus standard bowel preparations in patients aged 18–85 years. Treatment-blinded assessment of colon cleansing quality was performed by both site colonoscopists (SC; who also detected all lesions per local practice) and by central readers (CR). Two validated cleansing scales were used: the Harefield Cleansing Scale (HCS) and the Boston Bowel Preparation Scale (BBPS; only by CR). Patients with documented HCS cleansing grades D–A, overall BBPS scores 0–9, and overall colon lesion counts were included in this analysis. Logistic regression trends were fitted to polyp- (PDR) and adenoma (ADR) detection rates, using cleansing quality as a covariate.

Results Out of 1,985 randomised patients, 1,749 patients were included (table 1). With site colonoscopists' HCS grades, the logistic regression for relative lesion detection demonstrated an odds ratio of 1.17, i.e. for each incremental increase in the HCS colon cleansing grade from D to A there was a 1.17 times increase in both PDR ($P=0.009$) and ADR ($P=0.019$). With central readers, the corresponding increase was 1.24 times for PDR ($P=0.005$) and 1.26 times for ADR ($P=0.006$). With central readers, each incremental increase in the successful BBPS scores 6–9 resulted in a 1.08 times increase in PDR ($P<0.001$) and 1.10 times increase in ADR ($P<0.001$) versus failing BBPS scores 0–5.

Conclusions Adopting a better bowel preparation remains a good way to improve quality in colonoscopy. With both HCS and BBPS, an increased overall colon cleansing quality was associated with greater overall colon PDR and ADR across the full range from cleansing failures and up to high-quality cleansing.

Abstract PTH-028 Table 1 Overall colon cleansing quality and relative lesion detection

	HCS Grade D-A assessed by site colonoscopists	HCS Grade D-A assessed by central readers	Overall BBPS Score 0– 9 assessed by central readers
Patients, N	1,749	1,749	1,749
Relative lesion detection, odds ratio (95% CI); P-value			
PDR	1.17 (1.04–1.31); 0.009	1.24 (1.07–1.43); 0.005	1.08 (1.03–1.13); <0.001
ADR	1.17 (1.03–1.33); 0.019	1.26 (1.07–1.49); 0.006	1.10 (1.05–1.15); <0.001

PTH-029 CLOSURE OF GASTROGASTRIC FISTULAS WITH AN OVER-THE-SCOPE-CLIP (OTSC) – A LARGE TERTIARY HOSPITAL EXPERIENCE

Thomas Hollingworth*, Philip Boger, Emily Clarke, Praful Patel, Charlotte Rutter, Trevor Smith, Imdadur Rahman. *University Hospital Southampton, Southampton, UK*

10.1136/gutjnl-2019-BSGAbstracts.54

Introduction Gastrocutaneous fistulae (GF) are a rare, but difficult to manage complication after percutaneous endoscopic gastrostomy (PEG) tube removal. In cases, refractory to conventional medical management various approaches have been

used for their treatment including; surgical closure, through the scope clipping and endoscopic suturing with variable results. The over-the-scope-clip (OTSC) has an emerging role in the endoscopic closure of gastrointestinal wall defects, including persistent GF. The aim of this study was to assess the efficacy and safety of the use of OTSC for the closure of persistent GF.

Methods A prospectively kept database was analysed from September 2016 to January 2019 was undertaken of all persistent GF using an OTSC 12/6 GF clip. Prior to the deployment of an OTSC, the fistulous tract was disrupted using a wire brush, which also acted as a guide for placement. The use of ancillary techniques such as snare debulking or knife resection was utilised if needed. Primary outcome measures were; successful deployment of the OTSC, procedure time, complications and 30 day success. Secondary outcome measures were PEG dwell time prior to removal, time from diagnosis to closure and sedation type.

Results A total of 22 procedures were performed, on 12 male & 10 female patients with a mean age of 47. Median PEG dwell time was 16 months prior to removal. 64% of the procedures were performed with conscious sedation, with 36% requiring enhanced sedation with anaesthetic support. Technical success was 100%, with 2 procedures requiring ancillary techniques to facilitate the deployment of the OTSC, resulting in 1 complication of intra-procedural bleeding (stopped endoscopically). The median procedure time was 14 mins (range 9–35). A 30 & 90 day success was reported in 96% cases, with only one fistula recurring.

Discussion This is the largest cohort of patients with a persistent GF treated with an OTSC. This evolving procedure is an effective and safe method for the treatment of persistent GF. It has a much lower morbidity compared to surgery and shorter procedure times than more invasive endoscopic treatment options, such as endoscopic suturing.

PTH-030 OUTCOMES OF HEMOSPRAV USE IN PEPTIC ULCER UPPER GASTROINTESTINAL BLEEDS: OUTCOMES FROM THE HEMOSPRAV REGISTRY

^{1,2}Mohamed Hussein*, ²Durayd Alzoubaidi, ³Miguel Fraile, ³Jacobo Ortiz Fernandez-sordo, ³Krish Ragunath, ⁴Radu Rusu, ⁴John Dunn, ¹⁴Johannes Rey, ⁵Shraddha Gulati, ⁵Bu'Hussain Hayee, ⁶Selena Dixon, ⁶Sulleman Moreea, ⁷Duncan Napier, ⁷John Anderson, ⁸Martin Dahan, ⁹Max Hu, ⁹Patricia Duarte, ⁹Phil Boger, ¹⁰John McGoran, ¹⁰Inder Mainie, ¹¹Alberto Murino, ¹¹Sina Jameie- oskoeei, ¹¹Edward Despott, ¹²Cora Steinheber, ¹²Martin Goetz, ¹³Sharmila Subramaniam, ¹³Pradeep Bhandari, ^{1,2}Laurence Lovat, ⁸Emmanuel Coron, ¹⁴Ralf Keisslich, ^{1,2}Rehan Haidry. ¹UCLH, UK; ²UCL, UK; ³Nottingham Digestive Diseases Centre, UK; ⁴Guys and St Thomas Hospitals, UK; ⁵Kings college Hospital, UK; ⁶Bradford Teaching Hospital NHS Trust, UK; ⁷Gloucestershire Hospitals NHS Foundation Trust, UK; ⁸University Hospital of Nantes, France; ⁹University Hospital Southampton, UK; ¹⁰Belfast NHS Trust, UK; ¹¹Royal Free Hospital, UK; ¹²Tübingen University Hospital, UK; ¹³University of Portsmouth, UK; ¹⁴Horst Schmidt Kliniken, Germany

10.1136/gutjnl-2019-BSGAbstracts.55

Introduction Peptic ulcers are the commonest cause of upper Gastrointestinal bleeding (UGIB). Hemospray (Cook Medical, North Carolina, USA) is a novel haemostatic powder aimed to treat UGIB. The aim of this study is to look at outcomes in patients with peptic ulcer GI bleeding treated with hemospray in 13 centres.

Methods Data was prospectively collected on hemospray use in UGIBs in the UK, France and Germany (Jan'16–Sept'18). Hemospray was used for peptic ulcer UGIBs as a